eli lilly glp-1 agonist Lilly's oral pill may help people with Type 2 diabetes lose 'significant' weight, study finds Orforglipron: Eli Lilly's New Oral

Pharmaceutical GLP-1 agonists produce sustained receptor activation at levels far exceeding what natural GLP-1 achieves, even after meals

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 digital issues and online access to articles $119.00 per year only $9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

[DOI] [PubMed] [Google Scholar] 35.Greco EV, Russo G, Giandalia A, et al

Registration will open in January.

doi: 10.3389/fncel.2023.1136070